Engineered Ultrasmall Nanoparticle Drug‐Immune Conjugates with “Hit and Run” Tumor Delivery to Eradicate Gastric Cancer (Adv. Therap. 3/2023)

Engineered Ultrasmall Nanoparticle Drug‐Immune Conjugates with “Hit and Run” Tumor Delivery to Eradicate Gastric Cancer (Adv. Therap. 3/2023)

Receptor‐mediated endocytosis of a precision engineered HER2‐targeting ultrasmall silica nanoparticle drug conjugate after binding the HER2 extracellular domain on gastric cancer cells. This is reported by Ulrich Wiesner, J. Anand Subramony, Michelle S. Bradbury, and co‐workers in article number 220...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advanced therapeutics 2023-03, Vol.6 (3), p.n/a
Hauptverfasser: Zhang, Li, Aragon‐Sanabria, Virginia, Aditya, Anusha, Marelli, Marcello, Cao, Tianye, Chen, Feng, Yoo, Barney, Ma, Kai, Zhuang, Li, Cailleau, Thais, Masterson, Luke, Turker, Melik Z., Lee, Rachel, DeLeon, Gabriel, Monette, Sebastien, Colombo, Raffaele, Christie, Ronald J., Zanzonico, Pat, Wiesner, Ulrich, Subramony, J. Anand, Bradbury, Michelle S.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Receptor‐mediated endocytosis of a precision engineered HER2‐targeting ultrasmall silica nanoparticle drug conjugate after binding the HER2 extracellular domain on gastric cancer cells. This is reported by Ulrich Wiesner, J. Anand Subramony, Michelle S. Bradbury, and co‐workers in article number 2200209.
ISSN:2366-3987
2366-3987
DOI:10.1002/adtp.202370009